Big Pharma · Oncology

Novartis — Oncology

Rare DiseaseOncologyImmunologyCardiometabolicNeurology
Commission a Novartis report

Novartis across Oncology: Kisqali, and the 1 AXLRx report mapping the competitive, patient-flow and payer picture — each scoped to a single asset and cited to a live source.

All areas Rare DiseaseOncology
Market: All United States
AXLRx reports featuring Novartis — Oncology
Breast Cancer HR+/HER2-
CI
CI Oncology CI TeamLaunch Lead

US Breast Cancer HR+/HER2- Competitive Intelligence

Only ribociclib has posted consistent overall-survival wins in the three-way first-line CDK4/6 contest. MONALEESA-2 showed 63.9 versus 51.4 months (HR 0.76). The real competition has moved downstream, where 2023 approvals of an oral SERD and an AKT inhibitor carve the post-CDK4/6 line by biomarker.

US In-Market Read report →